Keyphrases
Asian Patients
100%
HER2+
100%
Lapatinib
100%
Advanced Breast Cancer
100%
Biomarker Studies
100%
HER2-targeted Therapy
100%
PIK3CA mutation
57%
P95HER2
57%
PTEN Deletion
57%
MRNA Level
42%
Progression-free Survival
42%
Human Epidermal Growth Factor Receptor 2 (HER2)
42%
Primary Diagnosis
42%
Tumor
28%
Clinical Outcomes
28%
Metastasis
28%
Trastuzumab
28%
Molecular Biomarkers
14%
Tissue Sampling
14%
Response Rate
14%
Potential Relationships
14%
Overall Survival
14%
Primary Tumor
14%
Treatment Response
14%
Co-occurrence Patterns
14%
Biopsy Specimen
14%
Tumor Biopsy
14%
Limited Availability
14%
Outcome-based
14%
Proportion of Tumour
14%
Paired Samples
14%
Non-interventional Study
14%
Metastatic Setting
14%
Conservation Level
14%
HER2 Receptor
14%
HER2+ Breast Cancer
14%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Lapatinib
100%
Biomarker Study
100%
Biological Marker
71%
Neoplasm
42%
Progression Free Survival
42%
Messenger RNA
42%
Trastuzumab
28%
Receptor
14%
Prevalence
14%
Overall Survival
14%
Primary Tumor
14%
Recurrent Disease
14%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
14%
Biochemistry, Genetics and Molecular Biology
Lapatinib
100%
Biomarker Study
100%
Downregulation
57%
Progression Free Survival
42%
Messenger RNA
42%
Trastuzumab
28%
Prevalence
14%
Overall Survival
14%